186 related articles for article (PubMed ID: 35615084)
1. Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis.
Taher NO; Ghaddaf AA; Al-Ghamdi SA; Homsi JJ; Al-Harbi BJ; Alomari LK; Almarzouki HS
Front Med (Lausanne); 2022; 9():884608. PubMed ID: 35615084
[TBL] [Abstract][Full Text] [Related]
2. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
5. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
Chang E; Josan AS; Purohit R; Patel CK; Xue K
Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
9. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
[TBL] [Abstract][Full Text] [Related]
10. Effect of ranibizumab on retinopathy of prematurity: A meta-analysis.
Wang Z; Zhang Z; Wang Y; Di Y
Front Pharmacol; 2022; 13():897869. PubMed ID: 36071843
[TBL] [Abstract][Full Text] [Related]
11. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
13. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
[TBL] [Abstract][Full Text] [Related]
14. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis.
Kong Q; Ming WK; Mi XS
BMJ Open; 2021 Feb; 11(2):e042384. PubMed ID: 33568373
[TBL] [Abstract][Full Text] [Related]
15. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis.
Wang SD; Zhang GM;
Int J Ophthalmol; 2020; 13(5):806-815. PubMed ID: 32420230
[TBL] [Abstract][Full Text] [Related]
16. Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis.
Diggikar S; Gurumoorthy P; Trif P; Mudura D; Nagesh NK; Galis R; Vinekar A; Kramer BW
Front Pediatr; 2023; 11():1055813. PubMed ID: 37009271
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor (VEGF) drugs compared to laser photocoagulation for treatment of type 1 retinopathy of prematurity.
González C R; Díaz C M; Garretón C R
Medwave; 2022 Jan; 22(1):e8507. PubMed ID: 35100244
[TBL] [Abstract][Full Text] [Related]
18. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Parravano M; Menchini F; Virgili G
Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis.
Alva N; Martínez AR; Ortiz-Saavedra B; Montes-Madariaga ES; Cotrina A; Caballero-Alvarado JA; Sah R; Barboza JJ
Front Pediatr; 2023; 11():1202927. PubMed ID: 37601137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
